ALSTON & BIRD LLP for NOVO NORDISK INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization).
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Taxation/Internal Revenue Code TAX
H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; Protecting Americans from Tax Hikes Act of 2015 (PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Health Issues HCR
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOYCE E GRESKO | — |
| CAITLIN MALONEY | — |
| EARL POMEROY | — |
| MARK RAYDER | — |
| COLIN ROSKEY | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| DANIELLE WHITE | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOYCE E GRESKO | — |
| CAITLIN MALONEY | — |
| MARK RAYDER | — |
| COLIN ROSKEY | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| DANIELLE WHITE | — |
| MARILYN K YAGER | — |
Budget/Appropriations BUD
Issues related to National Diabetes Prevention Program in H.R. 3020 and S.1695 FY16 Labor/HHS/Education Appropriations, P.L. 114-113 FY16 Consolidated Appropriations, and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| NOVO NORDISK US | Denmark | Denmark | 100.0% | — |
| NOVO NORDISK FONDEN (ULTIMATE PARENT COMPANY) | Denmark | Denmark | 100.0% | — |
| NOVO NORDISK A/S (OWNS 26.5% OF NN A/S) | Denmark | Denmark | 26.5% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.